300583 赛托生物
已收盘 02-27 15:00:00
资讯
新帖
简况
赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%
证券之星 · 02-24
赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%
赛托生物(300583.SZ)取得倍他米松原料药CEP证书
智通财经网 · 02-13
赛托生物(300583.SZ)取得倍他米松原料药CEP证书
赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%
证券之星 · 02-06
赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%
股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元
证券之星 · 02-02
股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元
赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%
证券之星 · 01-30
赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%
股市必读：赛托生物（300583）1月26日董秘有最新回复
证券之星 · 01-27
股市必读：赛托生物（300583）1月26日董秘有最新回复
赛托生物最新公告：收到化学原料药欧洲CEP证书
证券之星 · 01-20
赛托生物最新公告：收到化学原料药欧洲CEP证书
赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%
证券之星 · 01-16
赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%
股市必读：赛托生物（300583）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：赛托生物（300583）1月9日董秘有最新回复
赛托生物：开展AI技术探索性工作
证券之星 · 01-09
赛托生物：开展AI技术探索性工作
每周股票复盘：赛托生物（300583）归还5000万元募集资金
证券之星 · 01-03
每周股票复盘：赛托生物（300583）归还5000万元募集资金
赛托生物（300583）披露归还部分闲置募集资金补充流动资金的公告，12月31日股价上涨0.96%
证券之星 · 2025-12-31
赛托生物（300583）披露归还部分闲置募集资金补充流动资金的公告，12月31日股价上涨0.96%
赛托生物：截至2025年9月30日股东人数为13,737人
证券之星 · 2025-12-05
赛托生物：截至2025年9月30日股东人数为13,737人
赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书
智通财经 · 2025-11-11
赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书
赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准
智通财经 · 2025-11-03
赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准
赛托生物(300583.SZ)发布前三季度业绩，归母净亏损6923.03万元
智通财经 · 2025-10-28
赛托生物(300583.SZ)发布前三季度业绩，归母净亏损6923.03万元
赛托生物最新公告：子公司斯瑞药业收到地塞米松磷酸钠原料药CEP证书
证券之星 · 2025-10-09
赛托生物最新公告：子公司斯瑞药业收到地塞米松磷酸钠原料药CEP证书
赛托生物：公司当前聚集于既定的产业升级战略
证券之星 · 2025-09-23
赛托生物：公司当前聚集于既定的产业升级战略
赛托生物（300583）披露2025年半年度权益分派实施公告，9月16日股价上涨3.57%
证券之星 · 2025-09-16
赛托生物（300583）披露2025年半年度权益分派实施公告，9月16日股价上涨3.57%
股市必读：赛托生物（300583）9月12日董秘有最新回复
证券之星 · 2025-09-15
股市必读：赛托生物（300583）9月12日董秘有最新回复
加载更多
公司概况
公司名称：
山东赛托生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2017-01-06
主营业务：
山东赛托生物科技股份有限公司的主营业务是应用基因工程技术和微生物转化技术制造并销售甾体药物原料和中间体。公司的主要产品是雄烯二酮（4-AD）、雄二烯二酮（ADD）、9-羟基雄烯二酮（9OH-AD）、四烯物（3TR）、甲羟环氧孕酮（8DM）等甾体药物原料及中间体。公司入围国家工业和信息化部第五批国家级绿色工厂，获评山东省十强产业集群领军企业，子公司斯瑞药业获得山东省专精特新中小企业荣誉称号。
发行价格：
40.29
{"stockData":{"symbol":"300583","market":"SZ","secType":"STK","nameCN":"赛托生物","latestPrice":14.88,"timestamp":1772175798000,"preClose":14.93,"halted":0,"volume":2201600,"delay":0,"changeRate":-0.0033,"floatShares":186000000,"shares":190000000,"eps":-0.9105,"marketStatus":"已收盘","change":-0.05,"latestTime":"02-27 15:00:00","open":14.9,"high":15,"low":14.75,"amount":32662300,"amplitude":0.0167,"askPrice":14.88,"askSize":4,"bidPrice":14.87,"bidSize":24,"shortable":0,"etf":0,"ttmEps":-0.9105,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":14.93,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":16.42,"lowLimit":13.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":189702126,"isCdr":false,"pbRate":1.6,"roa":"--","roe":"--","epsLYR":-0.47,"committee":0.204819,"marketValue":2823000000,"turnoverRate":0.0118,"status":1,"floatMarketCap":2770000000},"requestUrl":"/m/hq/s/300583","defaultTab":"news","newsList":[{"id":"2613975387","title":"赛托生物（300583）披露关于子公司收到化学原料药欧洲CEP证书的公告，2月24日股价上涨1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613975387?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:37","pubTimestamp":1771929435,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，赛托生物报收于15.0元，较前一交易日上涨1.01%，最新总市值为28.46亿元。近日，山东赛托生物科技股份有限公司控股子公司山东斯瑞药业有限公司收到欧洲药品质量管理局签发的倍他米松原料药欧洲药典适用性证书，证书编号CEP 2024-446-Rev 00，有效期自2026年2月11日起五年内有效。倍他米松主要用于治疗过敏和自身免疫性炎症，2024年全球需求量近2吨。目前全球有7家倍他米松原料药生产企业持有有效CEP证书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2611132885","title":"赛托生物(300583.SZ)取得倍他米松原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2611132885","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611132885?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:36","pubTimestamp":1770971789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物 发布公告，公司控股子公司山东斯瑞药业有限公司近日收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书。涉及化学原料药名称：“BETAMETHASONE 倍他米松”。公司取得倍他米松原料药CEP证书，标志着公司该原料药可以在认可CEP 证书的国际市场进行销售，将为公司倍他米松原料药拓展国际市场带来积极的影响，进一步丰富公司的产品线，有利于提升公司在化学原料药领域的市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2609594391","title":"赛托生物（300583）披露控股子公司再次获得高新技术企业证书，2月6日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609594391?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:25","pubTimestamp":1770387920,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，赛托生物报收于14.81元，较前一交易日上涨0.14%，最新总市值为28.09亿元。该股当日开盘14.76元，最高14.96元，最低14.7元，成交额达2852.93万元，换手率为1.03%。近日，赛托生物披露《关于控股子公司再次获得高新技术企业证书的公告》。公告显示，公司控股子公司山东斯瑞药业有限公司通过高新技术企业审查，获得编号为GR202537002998的高新技术企业证书，发证时间为2025年12月8日，有效期三年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600041088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2608889755","title":"股市必读：赛托生物（300583）预计2025年全年扣非后净利润亏损6600万元至9100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889755","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889755?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:55","pubTimestamp":1769975709,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛托生物报收于14.5元，上涨0.76%，换手率1.7%，成交量3.17万手，成交额4559.83万元。赛托生物发布业绩预告，预计2025年全年归属净利润亏损6300万元至8800万元。公司公告汇总2025年度业绩预告山东赛托生物科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,300万元至8,800万元，上年同期亏损8,876.67万元；扣除非经常性损益后的净利润亏损6,600万元至9,100万元，上年同期亏损10,336.12万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583"],"gpt_icon":0},{"id":"2607428820","title":"赛托生物（300583）披露2025年度业绩预告，1月30日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607428820","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607428820?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:11","pubTimestamp":1769785870,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛托生物报收于14.5元，较前一交易日上涨0.76%，最新总市值为27.51亿元。该股当日开盘14.38元，最高14.58元，最低14.24元，成交额达4559.83万元，换手率为1.7%。公司于近日披露《2025年度业绩预告》。公告显示，山东赛托生物科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,300万元至8,800万元，上年同期亏损8,876.67万元；扣除非经常性损益后的净利润亏损6,600万元至9,100万元，上年同期亏损10,336.12万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2606922858","title":"股市必读：赛托生物（300583）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606922858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606922858?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:22","pubTimestamp":1769451733,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，赛托生物报收于15.24元，上涨2.42%，换手率3.36%，成交量6.25万手，成交额9433.44万元。董秘最新回复投资者： 请问公司25年四季度业绩怎么样？亏损有没有收窄？26年公司经营有什么扭亏为盈的布局吗？2025年度业绩预告披露时间请以公司公告为准。公司将做好生产经营，以业绩回报投资者的信任。交易信息汇总资金流向1月26日主力资金净流入543.51万元；游资资金净流入557.48万元；散户资金净流出1100.99万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2604956681","title":"赛托生物最新公告：收到化学原料药欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2604956681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604956681?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:01","pubTimestamp":1768899718,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司斯瑞药业近日收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书。该证书为公司糠酸氟替卡松原料药拓展国际市场带来积极影响，进一步丰富公司产品线，提升市场竞争力。但原料药销售受行业政策和市场需求影响，存在不确定性，投资者需注意相关投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000026060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2603994071","title":"赛托生物（300583）披露公司及子公司日常关联交易预计，1月16日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994071?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:46","pubTimestamp":1768574771,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，赛托生物报收于14.39元，较前一交易日下跌0.69%，最新总市值为27.3亿元。该股当日开盘14.53元，最高14.62元，最低14.3元，成交额达4224.9万元，换手率为1.57%。近日，赛托生物发布《关于公司及子公司日常关联交易预计的公告》，披露公司预计2026年与关联方天津信谊津津药业有限公司发生日常关联交易，主要为销售商品及提供劳务，预计金额不超过2,000.00万元，截至披露日已发生488.85万元。2025年实际发生金额为5,089.31万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2602550614","title":"股市必读：赛托生物（300583）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602550614?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:34","pubTimestamp":1768160050,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，赛托生物报收于14.35元，上涨1.06%，换手率1.56%，成交量2.9万手，成交额4128.91万元。董秘最新回复投资者： 请问我们公司在原有的产业领域是否开展了Ai研发？需要指出目前暂无实质性进展，请以公司公告为准，请投资者注意投资风险。交易信息汇总资金流向1月9日主力资金净流出89.5万元；游资资金净流入163.26万元；散户资金净流出73.76万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2602375122","title":"赛托生物：开展AI技术探索性工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375122","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375122?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:49","pubTimestamp":1767962956,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)01月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问我们公司在原有的产业领域是否开展了Ai研发？利用ai加快推进新药的研发？赛托生物回复：尊敬的投资者，您好！AI技术正在逐渐且深刻的改变各个行业，公司也在密切关注中，开展了一些探索性工作，尝试运用前沿AI技术助力合成生物学研究和研发。需要指出目前暂无实质性进展，请以公司公告为准，请投资者注意投资风险。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2600109887","title":"每周股票复盘：赛托生物（300583）归还5000万元募集资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2600109887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600109887?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:20","pubTimestamp":1767385221,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，赛托生物报收于13.69元，较上周的13.72元下跌0.22%。本周，赛托生物12月30日盘中最高价报13.88元。本周关注点公司公告汇总：赛托生物已归还5,000.00万元闲置募集资金至专用账户。赛托生物于2025年4月25日决议使用不超过15,000.00万元闲置募集资金暂时补充流动资金，期限不超过十二个月。2025年12月30日，公司已提前归还其中5,000.00万元至募集资金专户，并通知保荐机构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2595777219","title":"赛托生物（300583）披露归还部分闲置募集资金补充流动资金的公告，12月31日股价上涨0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777219?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:33","pubTimestamp":1767191594,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，赛托生物报收于13.69元，较前一交易日上涨0.96%，最新总市值为25.97亿元。该股当日开盘13.7元，最高13.76元，最低13.47元，成交额达2317.85万元，换手率为0.91%。公司近日发布公告称，山东赛托生物科技股份有限公司于2025年4月25日召开董事会及监事会会议，同意公司及全资子公司使用不超过15,000.00万元闲置募集资金暂时补充流动资金，使用期限自董事会批准之日起不超过十二个月，到期归还至募集资金专户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100045013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2589850982","title":"赛托生物：截至2025年9月30日股东人数为13,737人","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850982?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:36","pubTimestamp":1764905793,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日公司的股东人数是多少？谢谢赛托生物回复：尊敬的投资者，您好！截至2025年9月30日，公司股东人数为13,737人。您可在定期报告中查询当期股东人数或者携带身份证及持股书面文件现场查阅。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2582355110","title":"赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582355110","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582355110?lang=zh_cn&edition=full","pubTime":"2025-11-11 15:55","pubTimestamp":1762847746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布公告，公司控股子公司山东斯瑞药业有限公司近日收到国家药品监督管理局签发的糠酸莫米松《化学原料药上市申请批准通知书》。糠酸莫米松具有强效抗炎作用，可用于吸入剂和局部皮肤外用药，用作吸入剂时，可与β2-肾上腺素能激动剂和/或长效乙酰胆碱受体拮抗剂组合，主要用于治疗哮喘;用作皮肤外用药时，可治疗湿疹、神经性皮炎、异位性皮炎及皮肤瘙痒症等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛托生物(300583.SZ)子公司收到糠酸莫米松化学原料药上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2580123267","title":"赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580123267","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580123267?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:53","pubTimestamp":1762159996,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)公告，公司控股子公司山东斯瑞药业有限公司近日收到国家药品监督管理局签发的甲泼尼龙《化学原料药上市申请批准通知书》。甲泼尼龙是中效、不含卤素皮质激素类药物，用于危重疾病的急救，还可用于内分泌失调、风湿性疾病、胶原性病、皮肤疾病、过敏反应、眼科疾病、胃肠道疾病、血液疾病、白血病、休克、脑水肿、多发性神经炎、脊髓炎及防止癌症化疗引起的呕吐等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛托生物(300583.SZ)：甲泼尼龙化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2578938017","title":"赛托生物(300583.SZ)发布前三季度业绩，归母净亏损6923.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578938017","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578938017?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:41","pubTimestamp":1761640869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛托生物(300583.SZ)发布2025年三季度报告，该公司前三季度营业收入为7.49亿元，同比减少2.07%。归属于上市公司股东的净亏损为6923.03万元。归属于上市公司股东的扣除非经常性损益的净亏损为7238.79万元。基本每股亏损为0.36元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2574510451","title":"赛托生物最新公告：子公司斯瑞药业收到地塞米松磷酸钠原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2574510451","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574510451?lang=zh_cn&edition=full","pubTime":"2025-10-09 19:39","pubTimestamp":1760009979,"startTime":"0","endTime":"0","summary":"赛托生物(300583.SZ)公告称，公司控股子公司斯瑞药业近日收到欧洲药品质量管理局签发的地塞米松磷酸钠原料药欧洲药典适用性证书（CEP证书）。该证书有效期为自2025年10月1日起五年内有效。地塞米松磷酸钠是一种肾上腺皮质激素类药，主要用于过敏性与自身免疫性炎症性疾病。根据IQVIA数据统计，地塞米松磷酸钠原料药2024年全球需求量近10吨。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900029629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2569763353","title":"赛托生物：公司当前聚集于既定的产业升级战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2569763353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569763353?lang=zh_cn&edition=full","pubTime":"2025-09-23 11:33","pubTimestamp":1758598393,"startTime":"0","endTime":"0","summary":"证券之星消息，赛托生物(300583)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：能否介绍一下赛托生物在创新药领域的投资布局情况？赛托生物回复：尊敬的投资者，您好！公司积极关注行业中前景广阔的新兴领域，开展了一些探索性工作，短期内对公司的经营业绩不会造成重大影响。公司当前聚集于既定的产业升级战略，稳步推进原料药和制剂板块业务。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300014482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0},{"id":"2567489895","title":"赛托生物（300583）披露2025年半年度权益分派实施公告，9月16日股价上涨3.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567489895","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567489895?lang=zh_cn&edition=full","pubTime":"2025-09-16 22:48","pubTimestamp":1758034109,"startTime":"0","endTime":"0","summary":"截至2025年9月16日收盘，赛托生物报收于16.25元，较前一交易日上涨3.57%，最新总市值为30.83亿元。该股当日开盘15.69元，最高16.6元，最低15.59元，成交额达1.23亿元，换手率为4.09%。公司近日发布公告称，2025年半年度权益分派方案已获股东大会审议通过。本次权益分派股权登记日为2025年9月23日，除权除息日为2025年9月24日。分红对象为截至股权登记日在中国结算深圳分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600038494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300583"],"gpt_icon":0},{"id":"2567515727","title":"股市必读：赛托生物（300583）9月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2567515727","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567515727?lang=zh_cn&edition=full","pubTime":"2025-09-15 04:08","pubTimestamp":1757880497,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，赛托生物报收于15.81元，下跌0.63%，换手率1.4%，成交量2.6万手，成交额4121.65万元。董秘最新回复投资者： 据媒体报道，赛托生物与由生成式人工智能 驱动的临床阶段生物科技公司英硅智能达成战略合作，旨在运用前沿AI技术和优化生物系统工程化改造过程中的关键步骤，用于合成生物学研究及创新药物的研发。交易信息汇总资金流向9月12日主力资金净流出412.3万元；游资资金净流入114.59万元；散户资金净流入297.72万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300583","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772303054643,"stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0248},{"period":"3month","weight":-0.0255},{"period":"6month","weight":-0.0814},{"period":"1year","weight":-0.428},{"period":"ytd","weight":0.0869}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东赛托生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13737人(较上一季度增加7.91%)","perCapita":"13550股","listingDate":"2017-01-06","address":"山东省菏泽市定陶区东外环路南段","registeredCapital":"18970万元","survey":" 山东赛托生物科技股份有限公司的主营业务是应用基因工程技术和微生物转化技术制造并销售甾体药物原料和中间体。公司的主要产品是雄烯二酮（4-AD）、雄二烯二酮（ADD）、9-羟基雄烯二酮（9OH-AD）、四烯物（3TR）、甲羟环氧孕酮（8DM）等甾体药物原料及中间体。公司入围国家工业和信息化部第五批国家级绿色工厂，获评山东省十强产业集群领军企业，子公司斯瑞药业获得山东省专精特新中小企业荣誉称号。","listedPrice":40.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛托生物,300583,赛托生物股票,赛托生物股票老虎,赛托生物股票老虎国际,赛托生物行情,赛托生物股票行情,赛托生物股价,赛托生物股市,赛托生物股票价格,赛托生物股票交易,赛托生物股票购买,赛托生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛托生物(300583)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛托生物(300583)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}